Literature DB >> 6706980

Nonenzymatic glycosylation of human serum albumin alters its conformation and function.

N Shaklai, R L Garlick, H F Bunn.   

Abstract

Approximately 10% of the albumin in normal human serum is modified by nonenzymatic glycosylation, primarily at the epsilon-amino group of lysine residue 525. Incubation of albumin with glucose under physiological conditions in vitro resulted in glycosylation of the same residue. After separation of glycosylated human serum albumin from the nonglycosylated form by boronate affinity chromatography, the fluorescence emission characteristics of the sole tryptophan residue (Trp 214) were monitored. The quantum yield of tryptophan fluorescence for both in vivo and in vitro glycosylated albumin was reduced 30% relative to nonglycosylated albumin, and the maximal wavelength of the fluorescence emission band was shifted to shorter wavelengths. These observations show that nonenzymatic glycosylation induces a conformational change in human serum albumin. Ligand binding properties of glycosylated and unmodified albumin were compared. Hemin affinity was unaltered by glycosylation of albumin in vivo, whereas the affinity of bilirubin for glycosylated albumin was about 50% its value for the nonglycosylated form. The affinity of the long chain fatty acid cis-parinaric acid for albumin glycosylated in vivo and in vitro was reduced approximately 20-fold relative to nonglycosylated albumin. These differences in affinity suggest that lysine 525 plays a key role in the binding of physiologically important ligands to albumin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6706980

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  89 in total

1.  Acetoacetate promotes the formation of fluorescent advanced glycation end products (AGEs).

Authors:  Mousa Bohlooli; Mansour Ghaffari-Moghaddam; Mostafa Khajeh; Zohre Aghashiri; Nader Sheibani; Ali Akbar Moosavi-Movahedi
Journal:  J Biomol Struct Dyn       Date:  2016-02-23

2.  Comparison of modification sites formed on human serum albumin at various stages of glycation.

Authors:  Omar S Barnaby; Ronald L Cerny; William Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2010-10-27       Impact factor: 3.786

3.  Kinetics of fatty acid binding ability of glycated human serum albumin.

Authors:  Eiji Yamazaki; Minoru Inagaki; Osamu Kurita; Tetsuji Inoue
Journal:  J Biosci       Date:  2005-09       Impact factor: 1.826

Review 4.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

5.  Analysis of drug-protein binding using on-line immunoextraction and high-performance affinity microcolumns: Studies with normal and glycated human serum albumin.

Authors:  Ryan Matsuda; Donald Jobe; Jared Beyersdorf; David S Hage
Journal:  J Chromatogr A       Date:  2015-09-09       Impact factor: 4.759

6.  Albumin-Based Transport of Nonsteroidal Anti-Inflammatory Drugs in Mammalian Blood Plasma.

Authors:  Mateusz P Czub; Katarzyna B Handing; Barat S Venkataramany; David R Cooper; Ivan G Shabalin; Wladek Minor
Journal:  J Med Chem       Date:  2020-06-17       Impact factor: 7.446

7.  Ribosylation of bovine serum albumin induces ROS accumulation and cell death in cancer line (MCF-7).

Authors:  Mohd Shahnawaz Khan; Sourabh Dwivedi; Medha Priyadarshini; Shams Tabrez; Maqsood Ahmed Siddiqui; Haseeb Jagirdar; Abdulrahman M Al-Senaidy; Abdulaziz A Al-Khedhairy; Javed Musarrat
Journal:  Eur Biophys J       Date:  2013-11-12       Impact factor: 1.733

8.  Evidence of changes in renal charge selectivity in patients with type 1 (insulin-dependent) diabetes mellitus.

Authors:  A Kverneland; B Feldt-Rasmussen; P Vidal; B Welinder; L Bent-Hansen; U Søegaard; T Deckert
Journal:  Diabetologia       Date:  1986-09       Impact factor: 10.122

9.  Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy.

Authors:  J F Poduslo; G L Curran
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

10.  D-Ribosylated Tau forms globular aggregates with high cytotoxicity.

Authors:  Lan Chen; Yan Wei; Xueqing Wang; Rongqiao He
Journal:  Cell Mol Life Sci       Date:  2009-06-11       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.